Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies

Building on the success of the Cellistic Echo™-NK manufacturing platform for natural killer (NK) cells, the expanded Cellistic Echo™ portfolio leverages the company’s GMP manufacturing expertise and its EMA-certified, FDA- and PMDA-compliant manufacturing facility. Through dedicated platform development, these capabilities are extended to deliver scalable solutions across additional immune and regenerative cell types.

With the rising demand for cell-based therapies—driven by the increasing number and complexity of diseases—scalability and manufacturability remain limiting factors for many current development and manufacturing approaches. These factors impact patient access and program viability. Cellistic addresses these challenges through established GMP manufacturing platforms for iPSC-derived cell therapies that span the full development continuum, from cell line generation through each unit operation required to produce the cell type of interest, enabling scalable progression across clinical and commercial stages.

Gustavo Mahler, CEO of Cellistic, said: “The 2025 launch of the Echo™-NK manufacturing platform marked a significant advancement in cell therapy manufacturing.

“Building on this foundation and more than 15 years of experience in iPSC-derived cell therapy process development and GMP manufacturing, our team has developed three platforms designed to overcome the limitations of current cell therapy approaches. These off-the-shelf allogeneic cell therapies are a cost-effective way of ensuring more patients have access to these life-changing treatment options.”

Each of the three new platforms is designed to support iPSC-derived cell therapy development and manufacturing in distinct indications and modalities:

• Echo™-T addresses the inherent scalability and variability limitations of autologous T-cell therapies while preserving therapeutic relevance. The platform delivers iPSC-derived αβ T cells or Tregs, with a defined phenotype, stable identity, and predictable immune function, enabling efficient and reproducible development of immuno-oncology therapies.
• Echo™-Cardio delivers iPSC-derived cardiomyocytes with a well-defined, homogeneous phenotype and demonstrated functional relevance, enabling reproducible cardiac regenerative programs where biological fidelity is critical to therapeutic performance.
• Echo™-Endothelial provides iPSC-derived endothelial cells with consistent identity and function, supporting the scalable development of therapies targeting vascular biology, inflammation, and the tumor microenvironment.
  

“Cellistic was created to make iPSC-based cell therapies mainstream,” Mahler added. “The addition of the new Cellistic Echo™ platforms reflects that mission and demonstrates that our platforms, technologies, capabilities, and expertise are ready to supply the next generation of cell therapies.”

Adding to the Cellistic Pulse™ and Cellistic Echo™ portfolio, the new platforms provide drug developers with a turnkey path from gene-edited iPSCs to fully characterized, GMP-compliant cell therapy products across an expanded range of cell types. They are already supporting multiple active development programs, including programs approaching IND submission.